Global disparities in faecal microbiota transplantation research
Faecal microbiota transplantation (FMT) is recommended therapy for recurrent Clostridioides difficile infection in adult and paediatric patients 1 and is being explored as treatment for a growing range of microbiomemediated diseases. 2 Although microbiome-based therapies could play a key role in global health, 3,4 global FMT research remains inequitably distributed.
To explore the distribution of access to FMT research by geography and patient age, we searched the WHO's International Clinical Trials Registry Platform, 5 which aggregates 17 registries, including one African and one South American registry, using search terms "FMT", "f(a)ecal bacteriotherapy", "flora transplant*", "f(a)ecal transplant*", "f(a)ecal microbiota transplant*", and "intestinal microbiota transplant*" in December, 2019.
We identified 384 clinical studies involving FMT. Between 2010 and 2019, the number of studies increased, and the disease indications being explored diversified (figure). In 2013, 21 studies-most (17 of 21) studying C difficile infection or inflammatory bowel disease (IBD)-were registered. In 2017, 76 trials were registered, but less than a third (24 of 76) studied C difficile infection or IBD. Most studies were small (median enrolment target 35 patients, IQR 20-60), and early phase (170 [81%] of 209 were phase 1 or 2).
Most studies were registered in North America, Western Europe, and East Asia ( 
